Valeria Iansante


Post-Doctoral Research Associate


PhD in Biotechnology, University of L’Aquila, Italy, 2010
MSc, Biotechnology in Medicine, University of L’Aquila, Italy, 2006
BSc, Biotechnology, University of L’Aquila, Italy, 2004

research project title(s)

Co-encapsulation of human hepatocytes and mesenchymal stromal cells (MSCs) for the cellular therapy of acute liver failure (NIHR i4i project)

core expertise

Human hepatocytes isolation, culture, and cryopreservation
Hepatocytes/MSCs co-encapsulation in alginate
Optimisation of hepatocytes/MSCs microbeads performance and hepatocytes viability and functions
Molecular and cellular biology techniques

Tel: +44 20 32994447

main publications

PARP14 promotes the Warburg effect in hepatocellular carcinoma by inhibiting JNK1-dependent PKM2 phosphorylation and activation.
Iansante V, Choy PM, Fung S, Liu Y, Chai JG, Dyson J, D’Santos C, Williams R, Chokshi S, Anders RA, Bubici C and Papa S. Nature Communications, 2015; 6, article number: 7882. doi: 10.1038/ncomms8882.

MAPK signalling regulates the development of a cholangiocellular phenotype from HCC in post-TACE liver transplants.
Iansante V, Zen Y, Barbarulo A, Starling C, Chokshi S, Heaton N, Williams R, Bubici C, Quaglia A, Papa S. Gut 2012; 61:A416. doi:10.1136/gutjnl-2012-302514d.291.

Poly(ADP-ribose) polymerase family member 14 (PARP14) is a novel effector of the JNK2-dependent pro-survival signal in multiple myeloma.
Barbarulo A, Iansante V, Chaidos A, Naresh K, Rahemtulla A, Franzoso G, Karadimitris A, Haskard DO, Papa S, Bubici C. Oncogene, 2013; 32(36):4231-42. doi: 10.1038/onc.2012.448.

Biotech on the rise: the treatment of psoriasis with biological drugs.
Capece D, Iansante V, Fischietti M, Verzella D, Fargnoli MC, Peris K, Giacomelli R, Zazzeroni F, Alesse E. Psoriasis, InTech, 2012; Chapter 16:331-353. doi: 10.5772/26413.

Biotechnological approaches for the treatment of inflammatory diseases.
Iansante V, Capece D, Murgo S, Mancarelli MM, Zazzeroni F, Alesse E. Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, 2009; 8:51-71. doi: 10.2174/187152309787580793.

The glycosaminoglycan-binding domain of PRELP acts as a cell type-specific NF-kappaB inhibitor that impairs osteoclastogenesis.
Rucci N, Rufo A, Alamanou M, Capulli M, Del Fattore A, Ahrman E, Capece D, Iansante V, Zazzeroni F, Alesse E, Heinegård D, Teti A. J. Cell Biol., 2009; 187:669-683. doi: 10.1083/jcb.200906014.